Evidence map›Paper›PMID 27043525›Full record

ArticleInternational journal of molecular sciences2016

Apolipoprotein A1-Unique Peptide as a Diagnostic Biomarker for Acute Ischemic Stroke.

Xu Zhao, Yue Yu, Wenlong Xu, Lei Dong, Yuan Wang, Bing Gao, Guangyu Li, Wentao Zhang

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xu ZhaoSchool of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China. z.x41@mail.scut.edu.cn.
Yue YuSchool of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China. yueyu9023@gmail.com.
Wenlong XuDepartment of Neurosurgery, First Affiliated Hospital of China Medical University, Shenyang 110001, China. xwlcmu06@sina.com.
Lei DongDepartment of Neurosurgery, First Affiliated Hospital of China Medical University, Shenyang 110001, China. np-2813@163.com.
Yuan WangSchool of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China. yuanyuan03_03@163.com.
Bing GaoSchool of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China. binggao@scut.edu.cn.
Guangyu LiDepartment of Neurosurgery, First Affiliated Hospital of China Medical University, Shenyang 110001, China. tyjk1972@163.com.
Wentao ZhangSchool of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China. wtzhang9@gmail.com.
South China University of Technology · CNChina Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinically-informative biomarkers of ischemic stroke are needed for rapid diagnosis and timely treatment. In the present study, APOA1 unique peptide (APOA1-UP), a novel peptide biomarker, was identified and quantified by multiple reaction monitoring (MRM) using labeled reference peptide (LRP). Serum samples of 94 patients in the ischemic stroke group and 37 patients in the non-stroke group were analyzed for the levels of total APOA1-UP, low density lipoprotein cholesterol (LDL-C), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and total cholesterol (TC). Median ratio of total APOA1-UP/LRP was 2.14 (interquartile range, 0.40) in the non-stroke group and 1.32 (0.44) in the ischemic stroke group (p < 0.0001). The serum level of total APOA1-UP was independently correlated with the presence of ischemic stroke by multivariate logistic regression analysis (p < 0.0001). From the receiver operating characteristic (ROC) curve, the area under the curve (AUC) was 0.9750 and the optimal cutoff value of the serum APOA1-UP level was 1.80, which yielded a sensitivity of 90.63% and a specificity of 97.14%. The diagnostic efficiency of HDL-C was lower, with an AUC of 0.7488. Therefore, the serum level of APOA1-UP is a diagnostic biomarker candidate for ischemic stroke in the early stage.

Indexed as

AdultAgedApolipoprotein A-IArea Under CurveBiomarkersCase-Control StudiesCholesterolCholesterol, HDLCholesterol, LDLFemaleHumansLogistic ModelsMaleMiddle AgedROC CurveStrokeApolipoprotein A-IBiomarkersCholesterolCholesterol, HDLCholesterol, LDLTriglyceridesacute ischemic stroke (AIS)apolipoprotein A1 unique peptide (APOA1-UP)biomarkerhigh-density lipoprotein cholesterol (HDL-C)labeled reference peptide (LRP)multiple reaction monitoring (MRM)

Identifiers

PMID27043525
PMCPMC4848914
OpenAlexW2307570313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.